Trial Profile
An Open-label Study of Leukocyte Counts in the Cerebrospinal Fluid and Blood of Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment With Firategrast
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Firategrast (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 16 Mar 2010 Actual patient number (46) added as reported by ClinicalTrials.gov.
- 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Oct 2008 Status changed from recruiting to active, no longer recruiting.